Paper33340331
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B and 14 others. Cancer Immunol Immunother, 2021. Cited by 31 papers, by iCite.
Cite this record
ConductScience Library. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Papers, record 33340331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33340331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Carcinoma, Endometrioid | Major topic |
| Endometrial Neoplasms | Major topic |
| Lymphocytes, Tumor-Infiltrating | Major topic |
| Microsatellite Instability | Major topic |
| Mutation | Major topic |
| Tumor Microenvironment | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Middle Aged | |
| Prognosis | |
| Retrospective Studies | |
| Survival Rate |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30620402 | Cancer statistics, 2019. | CA Cancer J Clin | 2019 | https://conductscience.org/library/papers/30620402 | PubMed |
| 2 | 30550484 | Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. | Int J Gynecol Pathol | 2019 | https://conductscience.org/library/papers/30550484 | PubMed |
| 3 | 23868500 | Immune system: a double-edged sword in cancer. | Inflamm Res | 2013 | https://conductscience.org/library/papers/23868500 | PubMed |
| 4 | 26172027 | A clinically applicable molecular-based classification for endometrial cancers. | Br J Cancer | 2015 | https://conductscience.org/library/papers/26172027 | PubMed |
| 5 | 28061006 | Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. | Cancer | 2017 | https://conductscience.org/library/papers/28061006 | PubMed |
| 6 | 27006490 | Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27006490 | PubMed |
| 7 | 29344951 | The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. | J Pathol | 2018 | https://conductscience.org/library/papers/29344951 | PubMed |
| 8 | 27999680 | New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. | Gynecol Oncol Res Pract | 2016 | https://conductscience.org/library/papers/27999680 | PubMed |
| 9 | 28102259 | Elements of cancer immunity and the cancer-immune set point. | Nature | 2017 | https://conductscience.org/library/papers/28102259 | PubMed |
| 10 | 26181000 | Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. | JAMA Oncol | 2015 | https://conductscience.org/library/papers/26181000 | PubMed |
| 11 | 25977340 | Classifying Cancers Based on T-cell Infiltration and PD-L1. | Cancer Res | 2015 | https://conductscience.org/library/papers/25977340 | PubMed |
| 12 | 26989092 | Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. | Int Immunol | 2016 | https://conductscience.org/library/papers/26989092 | PubMed |
| 13 | 24925396 | T cell subpopulations. | Chem Immunol Allergy | 2014 | https://conductscience.org/library/papers/24925396 | PubMed |
| 14 | 25275055 | Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. | Anticancer Res | 2014 | https://conductscience.org/library/papers/25275055 | PubMed |
| 15 | 21897268 | Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. | Int J Gynecol Cancer | 2011 | https://conductscience.org/library/papers/21897268 | PubMed |
| 16 | 30401949 | T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. | Mod Pathol | 2019 | https://conductscience.org/library/papers/30401949 | PubMed |
| 17 | 30291344 | Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. | Mod Pathol | 2019 | https://conductscience.org/library/papers/30291344 | PubMed |
| 18 | 28344870 | Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28344870 | PubMed |
| 19 | 29464025 | Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. | Oncotarget | 2018 | https://conductscience.org/library/papers/29464025 | PubMed |
| 20 | 30530592 | Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. | J Immunol | 2019 | https://conductscience.org/library/papers/30530592 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42936408 | Functional single-cell omics in gynecological cancers immunotherapy: from heterogeneity dissection to clinical translation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42936408 | PubMed |
| 41891942 | ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities. | J Pathol Clin Res | 2026 | https://conductscience.org/library/papers/41891942 | PubMed |
| 41528614 | Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41528614 | PubMed |
| 41476451 | Estrogen receptor α expression in tumor-infiltrating lymphocytes from patients with endometrial cancer. | Oncol Lett | 2026 | https://conductscience.org/library/papers/41476451 | PubMed |
| 41472355 | Diagnostic Challenges and Clinical Implications of Microsatellite Instability/Mismatch Repair Deficiency in Solid Tumors. | Cancer Res Treat | 2026 | https://conductscience.org/library/papers/41472355 | PubMed |
| 41394227 | Analysis of the Clinicopathological Characteristics of Different Molecular Subtypes in Endometrial Cancer: A Retrospective Single Center Study. | Int J Gen Med | 2025 | https://conductscience.org/library/papers/41394227 | PubMed |
| 41312167 | Navigating tumour microenvironment in endometrial carcinoma: a comprehensive review integrating immunohistochemistry, single-cell RNA-sequencing and spatial transcriptomics. | Front Oncol | 2025 | https://conductscience.org/library/papers/41312167 | PubMed |
| 40940815 | Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications. | Cells | 2025 | https://conductscience.org/library/papers/40940815 | PubMed |
| 40894206 | Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40894206 | PubMed |
| 40321963 | The prognostic implication of polymerase epsilon-mutated endometrial cancer. | Tzu Chi Med J | 2025 | https://conductscience.org/library/papers/40321963 | PubMed |
| 39751650 | Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/39751650 | PubMed |
| 39730507 | A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer. | Sci Rep | 2024 | https://conductscience.org/library/papers/39730507 | PubMed |
| 38585471 | Assessment of Immune Status in Patients with Mismatch Repair Deficiency Endometrial Cancer. | J Inflamm Res | 2024 | https://conductscience.org/library/papers/38585471 | PubMed |
| 38305309 | TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification. | Recent Pat Anticancer Drug Discov | 2025 | https://conductscience.org/library/papers/38305309 | PubMed |
| 37568665 | Tumor Immune Microenvironment in Gynecologic Cancers. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37568665 | PubMed |
| 37568650 | Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37568650 | PubMed |
| 37035329 | Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37035329 | PubMed |
| 36937436 | ImmuneScore of eight-gene signature predicts prognosis and survival in patients with endometrial cancer. | Front Oncol | 2023 | https://conductscience.org/library/papers/36937436 | PubMed |
| 36675532 | Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer. | J Clin Med | 2023 | https://conductscience.org/library/papers/36675532 | PubMed |
| 36612250 | Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36612250 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| FOXP3 | 50943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
| MLH1 | 4292 | PubTator's text mining | https://conductscience.org/library/genes/4292 | NCBI Gene |
| MSH2 | 4436 | PubTator's text mining | https://conductscience.org/library/genes/4436 | NCBI Gene |
| MSH6 | 2956 | PubTator's text mining | https://conductscience.org/library/genes/2956 | NCBI Gene |
| PMS2 | 5395 | PubTator's text mining | https://conductscience.org/library/genes/5395 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33340331
GET https://conductscience.org/api/papers/v1/33340331/references?page=2